China-based Shanghai Henlius Biotech (HKG: 2696) has announced a strategic clinical study cooperation agreement with Shantou Central Hospital. The partnership aims to leverage Henlius’s clinical development and operational expertise with Shantou Central Hospital’s leading disciplinary advantages and comprehensive medical service capabilities. The collaboration will focus on scientific research exchange, personnel training, hospital management, platform construction, and more. Financial details of the agreement were not disclosed.
Shantou Central Hospital Profile
Founded in 1922, Shantou Central Hospital is one of the first Class 3A hospitals in China. The hospital boasts “two stations and multiple centers,” including the Guangdong provincial science and technology expert workstation, the Guangdong provincial doctor workstation, and the East Guangdong lung cancer clinical center of the Guangdong Lung Cancer Research Institute. It also has four scientific research platforms: the national biological specimen bank, the central laboratory, the clinical medical research center, and the follow-up center. Shantou Central Hospital is a national drug clinical trial institution, a national general practitioner training base, and a national standardized training base for residents, among other accolades.
Future Plans
Through this strategic cooperation, Henlius Pharmaceutical and Shantou Central Hospital will work together to enhance clinical research capabilities, improve medical service quality, and foster innovation in healthcare. This partnership is expected to drive significant advancements in clinical development and contribute to the broader healthcare ecosystem in China.-Fineline Info & Tech
